Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …
A novel NET-related gene signature for predicting DLBCL prognosis
H Shi, Y Pan, G Xiang, M Wang, Y Huang, L He… - Journal of Translational …, 2023 - Springer
Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy.
Neutrophil extracellular traps (NETs) are pathogen-trapping structures in the tumor …
Neutrophil extracellular traps (NETs) are pathogen-trapping structures in the tumor …
FOXP3 (in) stability and cancer immunotherapy
K Mortezaee - Cytokine, 2024 - Elsevier
Dysregulation of regulatory T cells (Tregs) is described in the context of inflammatory and
autoimmune diseases, and cancer. Forkhead box P3 (FOXP3) is a transcription factor that its …
autoimmune diseases, and cancer. Forkhead box P3 (FOXP3) is a transcription factor that its …
FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer
H Li, N Zheng, A Guo, W Tang, M Li, Y Cao, X Ma… - Cell Death & …, 2024 - nature.com
Programmed cell death 1 ligand 1 (PDL1)/programmed cell death 1 (PD1) blockade
immunotherapy provides a prospective strategy for the treatment of colorectal cancer (CRC) …
immunotherapy provides a prospective strategy for the treatment of colorectal cancer (CRC) …
[HTML][HTML] RAB22A as a predictor of exosome secretion in the progression and relapse of multiple myeloma
B Fan, L Wang, J Wang - Aging (Albany NY), 2024 - ncbi.nlm.nih.gov
Background: Multiple myeloma (MM) is an incurable malignant plasma cell disease. We
explored the role of RAB22A in exosome secretion, epithelial-mesenchymal transition (EMT) …
explored the role of RAB22A in exosome secretion, epithelial-mesenchymal transition (EMT) …
5-Fluorouracil resistance-based immune-related gene signature for COAD prognosis
H Yan, Q Ou, Y Chang, J Liu, L Chen, D Guo, S Zhang - Heliyon, 2024 - cell.com
Background Drug resistance is the primary obstacle to advanced tumor therapy and the key
risk factor for tumor recurrence and death. 5-fluorouracil (5-FU) chemotherapy is the most …
risk factor for tumor recurrence and death. 5-fluorouracil (5-FU) chemotherapy is the most …
Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer
MA De Velasco, Y Kura, K Fujita… - International Journal of …, 2024 - Wiley Online Library
Human prostate cancer is a heterogenous malignancy that responds poorly to
immunotherapy targeting immune checkpoints. The immunosuppressive tumor …
immunotherapy targeting immune checkpoints. The immunosuppressive tumor …
Immune Checkpoint Blockade Delays Cancer and Extends Survival in Murine DNA Polymerase Mutator Syndromes
Mutations in polymerases Pold1 and Pole exonuclease domains in humans are associated
with increased cancer incidence, elevated tumor mutation burden (TMB) and response to …
with increased cancer incidence, elevated tumor mutation burden (TMB) and response to …